MSLE Stock Chart & Stats
$8.66
$0.00(0.00%)
At close: 4:00 PM EST
$8.66
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.29 - $13.39
Previous CloseN/A
VolumeN/A
Average Volume (3M)46.60K
Market Cap
$166.17M
Enterprise Value$134.33M
Total Cash (Recent Filing)$61.74M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 25, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding21,216,438
10 Day Avg. Volume87,255
30 Day Avg. Volume46,596
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.36
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$24.80Price Target Upside186.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free structure reduces mandatory financing costs and refinancing exposure, giving Satellos greater flexibility while it develops its therapies. Meaningful equity provides a solvency cushion, although continued losses could gradually reduce that protection if cash consumption persists.
Defined Regenerative Medicine FocusSatellos has a clearly defined therapeutic strategy centered on regenerative medicine and a specific initial disease target. A focused program can concentrate scarce development resources and create a coherent path toward clinical validation if the approach proves effective.
Recent Cash-Burn ModerationAlthough cash generation remains negative, the improvement in free cash flow growth indicates that the pace of deterioration may be moderating. Sustaining this trend could extend financial runway and support continued development before revenue generation becomes possible.
Bears Say
No Revenue And Widening LossesSatellos has not yet demonstrated commercial revenue, while losses have more than doubled from 2023 to the latest TTM period. This combination shows that development spending is rising without operating leverage, leaving future progress dependent on successful commercialization.
Persistent Cash BurnThe company is converting its reported losses into substantial cash outflows, with TTM free cash flow materially more negative than in 2023. Continued burn can reduce financial flexibility and may require additional funding before products generate revenue.
Negative Returns And Equity ErosionA deeply negative return on equity indicates that shareholder capital is currently supporting losses rather than producing returns. Equity volatility, including a decline from 2024 to 2025, reinforces the risk that ongoing development spending will erode the balance-sheet cushion over time.
Satellos Bioscience News
MSLE FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was $5.29 and its highest was $13.39 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is $166.17M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Nov 25, 2026 which is in 47 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Aug 13, 2026. The company reported -$0.547 earnings per share for the quarter, missing the consensus estimate of -$0.51 by -$0.037.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.6.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 21,216,438 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -$0.547 in its last earnings report, missing expectations of -$0.51. Following the earnings report the stock price went down -2.138%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in MSLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.80 (186.37% Upside)
$24.80 (186.37% Upside)
Insider Transactions
Bought Shares
Worth $120.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.38%
12-Months-Change
Fundamentals
Return on Equity
-72.67%
Trailing 12-Months
Asset Growth
59.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
MSLE Stock 12 Month Forecast
Average Price Target
$24.80
▲(186.37% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Ownership Overview
6.67% Insiders
1.62% Mutual Funds
27.28% Other Institutional Investors
64.43% Public Companies and
Individual Investors